Novo and Lilly Reduce Prices of Weight-Loss Drugs in China

Novo Nordisk and Eli Lilly have taken a major step in China’s healthcare market by cutting prices of their leading weight-loss drugs, a move that could expand access for millions of patients and reshape competition in the pharmaceutical sector. Novo and Lilly reduced prices as China faces rising obesity rates, stronger local competition, and upcoming patent expiries for key medicines.